Cargando…
Validation of prognostic scoring and assessment of clinical benefit for patients with bone sarcomas enrolled in phase I clinical trials
BACKGROUND: We sought to validate the Royal Marsden Hospital (RMH) and MD Anderson Cancer Center (MDACC) prognostic scoring systems for the selection of bone sarcoma patients for phase I clinical trials and to identify additional risk factors related to survival. PATIENTS AND METHODS: We retrospecti...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5325454/ https://www.ncbi.nlm.nih.gov/pubmed/27486883 http://dx.doi.org/10.18632/oncotarget.10910 |
_version_ | 1782510388417396736 |
---|---|
author | Livingston, J. Andrew Hess, Kenneth R. Naing, Aung Hong, David S. Patel, Shreyaskumar Benjamin, Robert S. Ludwig, Joseph A. Conley, Anthony Herzog, Cynthia E. Anderson, Pete Meric-Bernstam, Funda Kurzrock, Razelle Subbiah, Vivek |
author_facet | Livingston, J. Andrew Hess, Kenneth R. Naing, Aung Hong, David S. Patel, Shreyaskumar Benjamin, Robert S. Ludwig, Joseph A. Conley, Anthony Herzog, Cynthia E. Anderson, Pete Meric-Bernstam, Funda Kurzrock, Razelle Subbiah, Vivek |
author_sort | Livingston, J. Andrew |
collection | PubMed |
description | BACKGROUND: We sought to validate the Royal Marsden Hospital (RMH) and MD Anderson Cancer Center (MDACC) prognostic scoring systems for the selection of bone sarcoma patients for phase I clinical trials and to identify additional risk factors related to survival. PATIENTS AND METHODS: We retrospectively reviewed the baseline characteristics and outcomes of 92 bone sarcoma patients who were referred to MDACC's Phase I Clinical Trials Program. RESULTS: Ninety-two patients with Ewing sarcoma (N = 47), osteosarcoma (N = 22), chondrosarcoma (N = 16), and other tumors (N = 7) were evaluated; 78 were enrolled in at least 1 of 43 different phase I trials. The median overall survival (OS) was 8.8 months (95% confidence interval [CI] = 6.8–13.7 months). Independent factors that predicted shorter survival were male sex, >2 metastatic sites, >3 previous therapies, hemoglobin level <10.5 g/dL, platelet count >200 x10(3)/L, creatinine level ≥1.3 mg/dL, and lactate dehydrogenase level >ULN. Patients with good RMH scores (0-1) had longer OS than patients with poor RMH scores (2-3) (HR = 5.8, 95% CI = 2.9–11.0; P < 0.0001), as did patients with low MDACC scores (0-1) as compared to patients with higher MDACC scores (2–4) (HR = 3.2, 95% CI = 1.9–5.6; P < 0.0001). CONCLUSION: The RMH prognostic score can be used to predict the OS of bone cancer patients referred for phase I trials. The MDACC score added no value to the RMH score and therefore does not have a role in assessment of patients with bone tumors. Patients with advanced bone sarcomas should be considered for phase I trials. |
format | Online Article Text |
id | pubmed-5325454 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-53254542017-03-23 Validation of prognostic scoring and assessment of clinical benefit for patients with bone sarcomas enrolled in phase I clinical trials Livingston, J. Andrew Hess, Kenneth R. Naing, Aung Hong, David S. Patel, Shreyaskumar Benjamin, Robert S. Ludwig, Joseph A. Conley, Anthony Herzog, Cynthia E. Anderson, Pete Meric-Bernstam, Funda Kurzrock, Razelle Subbiah, Vivek Oncotarget Clinical Research Paper BACKGROUND: We sought to validate the Royal Marsden Hospital (RMH) and MD Anderson Cancer Center (MDACC) prognostic scoring systems for the selection of bone sarcoma patients for phase I clinical trials and to identify additional risk factors related to survival. PATIENTS AND METHODS: We retrospectively reviewed the baseline characteristics and outcomes of 92 bone sarcoma patients who were referred to MDACC's Phase I Clinical Trials Program. RESULTS: Ninety-two patients with Ewing sarcoma (N = 47), osteosarcoma (N = 22), chondrosarcoma (N = 16), and other tumors (N = 7) were evaluated; 78 were enrolled in at least 1 of 43 different phase I trials. The median overall survival (OS) was 8.8 months (95% confidence interval [CI] = 6.8–13.7 months). Independent factors that predicted shorter survival were male sex, >2 metastatic sites, >3 previous therapies, hemoglobin level <10.5 g/dL, platelet count >200 x10(3)/L, creatinine level ≥1.3 mg/dL, and lactate dehydrogenase level >ULN. Patients with good RMH scores (0-1) had longer OS than patients with poor RMH scores (2-3) (HR = 5.8, 95% CI = 2.9–11.0; P < 0.0001), as did patients with low MDACC scores (0-1) as compared to patients with higher MDACC scores (2–4) (HR = 3.2, 95% CI = 1.9–5.6; P < 0.0001). CONCLUSION: The RMH prognostic score can be used to predict the OS of bone cancer patients referred for phase I trials. The MDACC score added no value to the RMH score and therefore does not have a role in assessment of patients with bone tumors. Patients with advanced bone sarcomas should be considered for phase I trials. Impact Journals LLC 2016-07-28 /pmc/articles/PMC5325454/ /pubmed/27486883 http://dx.doi.org/10.18632/oncotarget.10910 Text en Copyright: © 2016 Livingston et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Clinical Research Paper Livingston, J. Andrew Hess, Kenneth R. Naing, Aung Hong, David S. Patel, Shreyaskumar Benjamin, Robert S. Ludwig, Joseph A. Conley, Anthony Herzog, Cynthia E. Anderson, Pete Meric-Bernstam, Funda Kurzrock, Razelle Subbiah, Vivek Validation of prognostic scoring and assessment of clinical benefit for patients with bone sarcomas enrolled in phase I clinical trials |
title | Validation of prognostic scoring and assessment of clinical benefit for patients with bone sarcomas enrolled in phase I clinical trials |
title_full | Validation of prognostic scoring and assessment of clinical benefit for patients with bone sarcomas enrolled in phase I clinical trials |
title_fullStr | Validation of prognostic scoring and assessment of clinical benefit for patients with bone sarcomas enrolled in phase I clinical trials |
title_full_unstemmed | Validation of prognostic scoring and assessment of clinical benefit for patients with bone sarcomas enrolled in phase I clinical trials |
title_short | Validation of prognostic scoring and assessment of clinical benefit for patients with bone sarcomas enrolled in phase I clinical trials |
title_sort | validation of prognostic scoring and assessment of clinical benefit for patients with bone sarcomas enrolled in phase i clinical trials |
topic | Clinical Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5325454/ https://www.ncbi.nlm.nih.gov/pubmed/27486883 http://dx.doi.org/10.18632/oncotarget.10910 |
work_keys_str_mv | AT livingstonjandrew validationofprognosticscoringandassessmentofclinicalbenefitforpatientswithbonesarcomasenrolledinphaseiclinicaltrials AT hesskennethr validationofprognosticscoringandassessmentofclinicalbenefitforpatientswithbonesarcomasenrolledinphaseiclinicaltrials AT naingaung validationofprognosticscoringandassessmentofclinicalbenefitforpatientswithbonesarcomasenrolledinphaseiclinicaltrials AT hongdavids validationofprognosticscoringandassessmentofclinicalbenefitforpatientswithbonesarcomasenrolledinphaseiclinicaltrials AT patelshreyaskumar validationofprognosticscoringandassessmentofclinicalbenefitforpatientswithbonesarcomasenrolledinphaseiclinicaltrials AT benjaminroberts validationofprognosticscoringandassessmentofclinicalbenefitforpatientswithbonesarcomasenrolledinphaseiclinicaltrials AT ludwigjosepha validationofprognosticscoringandassessmentofclinicalbenefitforpatientswithbonesarcomasenrolledinphaseiclinicaltrials AT conleyanthony validationofprognosticscoringandassessmentofclinicalbenefitforpatientswithbonesarcomasenrolledinphaseiclinicaltrials AT herzogcynthiae validationofprognosticscoringandassessmentofclinicalbenefitforpatientswithbonesarcomasenrolledinphaseiclinicaltrials AT andersonpete validationofprognosticscoringandassessmentofclinicalbenefitforpatientswithbonesarcomasenrolledinphaseiclinicaltrials AT mericbernstamfunda validationofprognosticscoringandassessmentofclinicalbenefitforpatientswithbonesarcomasenrolledinphaseiclinicaltrials AT kurzrockrazelle validationofprognosticscoringandassessmentofclinicalbenefitforpatientswithbonesarcomasenrolledinphaseiclinicaltrials AT subbiahvivek validationofprognosticscoringandassessmentofclinicalbenefitforpatientswithbonesarcomasenrolledinphaseiclinicaltrials |